On our screens:Stocks with no debt
Is the price fair?
What BIO's price assumes
Bio-Rad Laboratories, Inc. trades at 65.4× earnings against 30.9× for the median Medical Devices name, more expensive than its own group.
65.4
Trailing P/E · Medical Devices median 30.9 · 2.12× the median: the market pays up for this one
- Price / sales
- 2.90
Price / sales · as of 2026-Q1
- Free cash flow yield
- 4.5%
Free cash flow yield · Medical Devices median 3.9%
- Growth the price implies
- +7.1%
Growth the price implies · The price pays for +7.1% free cash flow growth a year for a decade; the business has delivered +41% a year over the last three.
Details›
- Price / book2026-Q1
- 1.10
- EV / EBIToperating margin 2.2%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 3.17
- Healthcare median P/E362 names
- 29.9
- Medical Devices median P/E39 names
- 30.9
- Free cash flow, trailing twelve months
- $357M
- Market capitalisation
- $7.98B
- 3-year revenue growth
- −2.3%
- 3-year free cash flow growth
- +41%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $31.20 |
| Its own P/E history, median | $68.80 |
| Its own P/E history, upper quartile | $83.02 |
| 52-week range | $241.71 – $390.31 |
| Today | $380.17 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
Ranks #21 of 29 by Smart Score